C-Reactive Protein Testing Market Growth, Restraints, Trends, Company Profiles, Analysis & Forecast Till 2028
The global C-reactive protein testing market size is expected to reach USD 1.93 Billion by 2028 and register a CAGR of 1.8% over the forecast period, according to the latest report by Reports and Data. Increasing incidence of cardiovascular and chronic inflammatory disease, rising adoption of C-reactive Protein (CRP) testing in primary care settings, and increasing application of CRP testing in diagnosis of inflammatory and infectious diseases are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing investment and funding to accelerate research on applications and importance of CRP are also expected to contribute to revenue growth of the market going ahead.
Furthermore, the report covers various important aspects of the industry
such current and emerging trends, updated outlines, growth factors, restraints,
growth prospects and opportunities, regulatory framework and government
policies, macro and micro economic factors, and other factors that enable to
draw projections for the estimated market growth in the forecast period.
Key companies operating in the global market and profiled in the report include:
Thermo Fisher
Scientific, Inc., F. Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics
Incorporated, Siemens, Abbott Laboratories, Laboratory Corporation of America
Holdings, Merck KGaA, Abaxis, Inc., Ortho Clinical Diagnostics, Getein Biotech,
Inc., HORIBA, Ltd., Randox Laboratories Ltd., Aidianm, and BODITECH MED INC
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4051
Some Key
Highlights From the Report:
·
Immunoturbidimetric assay segment is expected to
account for largest revenue share during the forecast period attributable to
rapid development and availability of cost-effective automated and sensitive
assays.
·
Cardiovascular disease segment is expected to
register robust revenue growth over the forecast period owing to increasing
global prevalence of cardiovascular conditions, growing demand for quick
diagnostic methods, rising need for early detection, and large number of
C-reactive protein tests performed for diagnosis of CVD.
·
Clinics segment is expected to register considerable
revenue growth between 2021 and 2028 owing to increasing adoption of POC CRP
testing in primary care settings, cost-effectiveness, and need for rapid and
accurate results.
·
North America is expected to account for largest
revenue share over the forecast period attributable to increasing incidence of
CVD, rheumatoid arthritis, and other inflammatory conditions, presence of
well-established healthcare infrastructure, and favorable reimbursement
scenario.
For the purpose of this report, Reports and Data has segmented the
C-reactive protein testing market based on assay type, application, end-use,
and region:
Assay Type
Outlook (Revenue, USD Billion; 2018-2028)
- ELISA
- Turbidometric
- Immunoturbidometric
Ask for discount @ https://www.reportsanddata.com/request-customization-form/4051
Application Outlook (Revenue, USD Billion; 2018-2028)
- Cardiovascular Diseases
- Cancer
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
- Endometriosis
- Lupus
- Others
End-use Outlook
(Revenue, USD Billion; 2018-2028)
- Clinics
- Hospitals
- Diagnostic Labs
Regional analysis covers:
·
North
America (U.S., Canada, Mexico)
·
Europe
(U.K., Italy, Germany, France, Rest of Europe)
·
Asia
Pacific (India, Japan, China, South Korea, Australia,
Rest of APAC)
·
Latin
America (Chile, Brazil, Argentina, Rest of Latin
America)
·
Middle
East & Africa (Saudi Arabia, U.A.E., South Africa,
Rest of MEA)
Speak to Analyst @ https://www.reportsanddata.com/speak-to-analyst-form/4051
Thank you for reading our report. To
know more about the customization of the report or further query about the
report, please get in touch with us. Our team will ensure the report is well
suited to your requirements.
Read More:
Comments
Post a Comment